Belite Bio Inc ADRBLTE
Price$162.98

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income -$77.6MTTM through 31 Dec 2025
Free Cash Flow -$37.1MTTM through 31 Dec 2025

Margins

Current

Returns

-10.1%ROE
-9.9%ROA

Balance Sheet Health

Current Ratio50.02x
Cash & Equivalents$352.9M

Quality Metrics

Altman Z-Score420.81
Piotroski F-Score3 / 9
Earnings-Beat Rate0.0%

Multi-Year Trend

Diluted EPS-$2.31TTM
'20'21'22'23'24'25
FY2025: $-2.31

Dividend

No dividend

Capital Allocation

R&D Spend$45.4M

Segment Performance

SegmentRevenueYoYOutlook
Biopharmaceutical Research and Development$0
View details

Rolling NDA submission to the FDA for tinlarebant in STGD1 was completed in June 2026, targeting potential commercial launch in 2027.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.